The European Commission Approves Revolution Medicines’ Daraxonrasib for Metastatic Pancreatic Cancer

The European Commission Approves Revolution Medicines’ Daraxonrasib for Metastatic Pancreatic Cancer

The European Commission has approved daraxonrasib, a once-daily oral monotherapy, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy, Revolution Medicines announced on November 16, 2026. The decision adds a RAS-targeted treatment option in a setting where choices beyond cytotoxic chemotherapy have been limited, and the indication covers patients with or without an identified tumor RAS mutation. The approval was based on the phase 3 RASolute 302 trial, which evaluated daraxonrasib against the investigator’s choice of chemotherapy.

European Review and Approved Indication

The European Commission’s decision followed a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use. Daraxonrasib underwent an expedited phased review under the agency’s Cancer Medicines Pathfinder project because of its potential to address a high unmet medical need.

The approval authorizes daraxonrasib as a single agent after at least one prior systemic therapy. It applies across all European Union member states and in Iceland, Norway, and Liechtenstein, the three additional countries in the European Economic Area. The United Kingdom and Switzerland have separate regulatory approval processes.

The release also describes a separate US indication. The US Food and Drug Administration approved daraxonrasib for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are ineligible for multiagent systemic therapy.

How Daraxonrasib Targets RAS

Daraxonrasib is an oral, noncovalent, multiselective RAS(ON) inhibitor that acts on the active form of RAS through a tri-complex mechanism. RAS helps regulate cell growth, and excessive RAS signaling is a feature of pancreatic adenocarcinoma. The pivotal study enrolled patients whose tumors carried several RAS variants and patients whose tumors had no identified RAS mutation.

Thomas Seufferlein, medical director of the Clinic for Internal Medicine I at Ulm University Hospital, said:

“For decades, physicians treating metastatic pancreatic cancer have had limited options beyond cytotoxic chemotherapy, underscoring the urgent need for new therapeutic approaches.”

Phase 3 RASolute 302 Trial Design and Results

RASolute 302 was a global, randomized phase 3 registrational trial in patients with previously treated metastatic pancreatic adenocarcinoma. Participants were assigned to daraxonrasib at an oral dose of 300 mg once daily or the investigator’s choice of one of four cytotoxic chemotherapy regimens used as standard care. The study enrolled patients with RAS G12 mutations, including G12D, G12V, and G12R, as well as patients without an identified tumor RAS mutation.

  • Primary endpoints in patients with RAS G12 mutations. The trial met both overall survival and progression-free survival endpoints in patients whose tumors harbored a RAS G12 mutation. A blinded independent central review assessed progression-free survival using RECIST 1.1.
  • Key secondary endpoints in the overall population. The trial also met the overall survival and progression-free survival endpoints in the intent-to-treat population, which included all enrolled patients with and without an identified tumor RAS mutation.
  • Additional secondary endpoints. The study also assessed objective response rate, duration of response, and patient-reported quality of life.

The initial results were presented at the 2026 American Society of Clinical Oncology Annual Meeting and published simultaneously in The New England Journal of Medicine. The approval announcement reports which survival endpoints were met and refers readers to the trial publication for the numerical efficacy results. Additional subgroup anaysis were presented at ESMO 2026.

European Commission

Safety Findings in the US Prescribing Information

The release includes safety information from the US prescribing information. The figures below describe adverse reactions among patients treated with daraxonrasib.

  • Dermatologic and soft tissue toxicity. Dermatologic toxicity occurred in 86% of patients, with grade 3 toxicity reported at 10%.
  • Manifestations included rash, pruritus, paronychia, dry skin, and skin fissures.
  • Stomatitis and oral disorders. Stomatitis occurred in 57% of patients, with grade 3 events reported at 9%. Oral manifestations included mouth ulcers and oral mucositis.
  • Diarrhea. Diarrhea occurred in 63% of patients, with grade 3 events reported at 6%.
  • Gastrointestinal perforation. Gastrointestinal perforation occurred in 0.9% of patients, with grade 3 events reported at 0.5%. One event was grade 4 and one was fatal.
  • Interstitial lung disease or pneumonitis. Interstitial lung disease or pneumonitis occurred in 2.4% of patients, with grade 3 events reported at 0.9%. One event was fatal.
  • Serious adverse reactions. These occurred in 30% of patients. Serious reactions reported in at least 2% were diarrhea (3.7%), pyrexia (3.3%), sepsis (2.9%), fatigue (2.1%), and hemorrhage (2.1%).
  • Permanent discontinuation. Adverse reactions led to permanent discontinuation in 2.9% of patients. Two patients (0.8%) discontinued because of rash.

Common adverse reactions. Reactions reported in at least 20% of patients included rash, diarrhea, stomatitis, nausea, fatigue, vomiting, abdominal pain, edema, decreased appetite, and hemorrhage.

The US prescribing information also warns of potential embryo-fetal harm based on animal findings. It describes preventive measures for dermatologic reactions, including topical corticosteroids, emollients, and sun protection, with prophylactic oral antibiotics considered. The prescribing information also outlines treatment interruption, dose reduction, or permanent discontinuation for certain adverse reactions based on their severity.

Revolution Medicines stated that it is working with national assessment and reimbursement bodies to make daraxonrasib available to eligible patients in the European Union. The timing of access will vary by country as national pricing, health technology assessment, and reimbursement processes are completed. Daraxonrasib also remains under investigation in global phase 3 registrational trials in pancreatic adenocarcinoma and metastatic RAS-mutant non-small cell lung cancer.

 Join OncoDaily’s How I Treat Pancreatic Cancer in 2026 virtual summit to hear how oncology experts weigh new evidence, choose among treatment options, and approach challenging cases in clinical practice.

The European Commission